The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
20-Oct-05
$NA
Target:
Drakkar Holdings SA (Adisseo Group)
Acquiror:
China National Chemical Corporation
Advised CVC Capital Partners on the divestiture of Adisseo via the sale of Drakkar Holdings SA to China National BlueStar, a subsidiary of state-owned diversified chemicals company China National Chemical Corporation. Adisseo is a leading player in the animal nutrition market
28-Nov-05
$103 million
Target:
Akzo Nobel N.V.
Acquiror:
Hexion Specialty Chemicals Inc.
(Ink and Adhesive Resins business) Advised Akzo Nobel N.V., a global leader in coatings, chemicals and healthcare on the sale of its Ink and Adhesive Resins business to Hexion Specialty Chemicals Inc
20-Feb-06
$254 million
Target:
Textile Effects
Acquiror:
Huntsman Corporation
(division of Ciba Specialty Chemicals AG)
Advised Ciba Specialty Chemicals AG on the sale of its global Textile Effects business
24-Mar-06
$21.2 billion
Target:
Schering AG
Acquiror:
Bayer AG
Advised Bayer on its public offer for Schering, an international pharmaceuticals group based in Berlin, Germany
03-May-07
$8.5 billion
Target:
IPSCO Inc.
Acquiror:
SSAB Svenskt Stål AB
Acted as lead financial advisor to SSAB Svenskt Stål AB on its acquisition of IPSCO Inc., a leading Canadian producer of energy tubulars and steel plate in North America with an annual steel making capacity of 4.3 million tons
31-Jul-07
$491 million
Target:
DEUTZ Power Systems
Acquiror:
3i
Sole advisor to DEUTZ AG on the divestiture of its division DEUTZ Power Systems, a leading manufacturer of gas fired engines for decentralized power generation
22-Jan-08
$3.4 billion
Target:
Ventana Medical Systems, Inc.
Acquiror:
Roche Holding Ltd.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of Ventana Medical Systems, Inc., a US based provider of histopathology diagnostic equipment
08-Oct-08
$NA
Target:
MAN Ferrostaal AG
Acquiror:
International Petroleum Investment Company (IPIC)
Advised MAN AG in relation to its 70% sale of MAN Ferrostaal AG, a worldwide supplier of industrial services for the construction of large-scale industrial plants and machine supply, to International Petroleum Investment Company (IPIC)
12-Oct-08
$6.0 billion
Target:
Hapag-Lloyd AG
Acquiror:
Albert Ballin KG
Advised TUI AG, Europe’s largest tourism company, on its sale of its shipping division Hapag-Lloyd AG, one of the leading global container shipping companies
12-Mar-09
$46.9 billion
Target:
Genentech, Inc.
Acquiror:
Roche Holding Ltd.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of the outstanding publicly held interest in Genentech, Inc., a leading biotechnology company
09-Nov-09
$327 million
Target:
Enzon Pharmaceuticals, Inc.
Acquiror:
Sigma-Tau Pharmaceuticals
Advised Enzon Pharmaceuticals, Inc., a biopharmaceutical company on the sale of its specialty pharmaceutical business to Sigma-Tau, an Italian pharmaceutical company
09-Feb-10
$672 million
Target:
SAS Group
Acquiror:
Norwegian Government
Advised the Norwegian Government on strategic and financial matters in relation to a refinancing including a conditional capital injection in SAS, the leading airline group in Northern Europe
16-Sep-10
$NA
Target:
KemFine UK Ltd
Acquiror:
AURELIUS AG
Advised KemFine Group Oy, a 3i portfolio company, on the sale of its UK-based fine chemicals business, KemFine UK Ltd, to AURELIUS AG
21-Sep-10
$234 million
Target:
Taro Pharmaceutical Industries
Acquiror:
Sun Pharmaceutical Industries Ltd.
Advised Sun Pharmaceutical Industries Ltd., the largest Indian pharmaceutical company by market capitalization, on its acquisition of a majority interest in Israeli based Taro Pharmaceutical Industries, a multinational generics pharmaceutical company
26-Nov-10
$118 million
Target:
Healthcare Australia
Acquiror:
Healthcare Locums
Advised CHAMP Private Equity on the sale of Healthcare Australia, a leading provider of nursing agency staff to public and private health institutions in Australia, to Healthcare Locums, a healthcare recruitment agency based in the UK
01-Dec-10
$100 million
Target:
Clyde Process Solutions plc
Acquiror:
S-Process Equipment International S.à r.l. (Schenck Process)
Advised S-Process Equipment International S.à r.l. (“Schenck Process”), a global leader in bulk material handling, providing applications incorporating weighing, feeding, screening and automation solutions, on its acquisition of Clyde Process Solutions plc, a global provider of pneumatic conveying and air filtration solutions for process industries
15-Dec-10
$12.9 billion
Target:
Alcon, Inc.
Acquiror:
Novartis AG
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company
15-Jan-11
$105 million
Target:
telerob Holding GmbH
Acquiror:
Cobham plc
Advised the shareholders of telerob Holding GmbH, a German-based market leader in the development and manufacture of advanced bomb disposal robots and integrated threat response vehicles, on the sale of the Company to Cobham plc, the UK-based, internationally operating aerospace, defence and security technology group
22-Jun-11
$NA
Target:
KemFine Group Oy
Acquiror:
CABB AG
Advised 3i on the disposal of KemFine Group Oy, a leading custom manufacturer of fine chemicals, to CABB AG
10-Nov-11
$318 million
Target:
MSF Sugar
Acquiror:
Mitr Phol Group
Advised MSF Sugar, Australia’s third largest producer and second largest exporter of sugar, on an acquisition proposal from Mitr Phol Sugar Corp. of Thailand at an offer value of ~31% premium to previous close
21-Nov-11
$689 million
Target:
iNova Pharmaceuticals
Acquiror:
Valeant Pharmaceuticals
Advised Archer Capital and Ironbridge Capital on the sale of iNova Pharmaceuticals, a leading pharmaceuticals company that sells and distributes a range of prescription and over-the-counter products in Australia, New Zealand, Asia and Southern Africa, to Valeant Pharmaceuticals
01-Mar-12
$NA
Target:
Minority stake in Stadler Rail
Acquiror:
Peter Spuhler
Advised Capvis, one of the leading buyout firms in Switzerland and one of the main mid-market private equity firms in German-speaking Europe, on the staged exit from of its 20% minority stake in Stadler Rail, by selling to Peter Spuhler, CEO and majority shareholder in Stadler Rail
07-Mar-12
$256 million
Target:
Aperio Group
Acquiror:
Amcor Limited
Advised Catalyst Investment Managers on the sale of its portfolio company Aperio Group, Australasia’s leading manufacturer of flexible packaging products, to Amcor Limited, a global leader in packaging solutions
26-Mar-12
$513 million
Target:
ISTA Pharmaceuticals, Inc.
Acquiror:
Bausch + Lomb, Inc.
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its sale to Bausch + Lomb, Inc., a global ophthalmic products company
28-Aug-12
$177 million
Target:
Goodman Fielder’s Australian and New Zealand edible fats and oils business (Integro)
Acquiror:
Graincorp
Advised Goodman Fielder, Australia’s leading listed food company, on the divestment of its Australian and New Zealand edible fats and oils business to a joint venture between Graincorp, an ASX listed international agribusiness company, and Gardner Smith